Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, First-in-Human Study of DS-9606a in Patients With Tumor Types Known to Express Claudin-6 (CLDN6)

NCT05394675 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT05394675
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05394675 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, First-in-Human Study of DS-9606a in Patients With Tumor Types Known to Express Claudin-6 (CLDN6)
Lead sponsor
Daiichi Sankyo
Phase
Phase 1
Overall status
Terminated
Start date
May 31, 2022
Completion date
February 6, 2026
Enrollment
88 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, germ cell tumor, metastatic cancer